Pipeline of Key Proprietary Products
We have a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer.
Development Candidates
ALKS 3831
Schizophrenia / Bipolar I Disorder*
ALKS 4230
Oncology (Intravenous Dosing)
Oncology (Subcutaneous Dosing)
Selective HDAC Inhibitors
Neurodegenerative Disorders (Orphan)
Neurodegenerative Disorders (Prevalent, Non-orphan)
Oncology
*PDUFA target action date of NDA resubmission: June 1, 2021